0000000000135970

AUTHOR

Dagmar Dilloo

showing 2 related works from this author

Health status, health-related quality of life, and socioeconomic outcome in childhood brain tumor survivors: a German cohort study

2019

Abstract Background With rising numbers of childhood cancer survivors, somatic and socioeconomic outcome as well as health-related quality of life (QoL) gain increasing relevance. Based on the first nationwide German Survey on Life Situation, State of Health, and Quality of Life of Childhood Cancer Survivors, the VIVE survey, we report the outcome of survivors of childhood brain tumors localized in the posterior fossa. Methods Two hundred seventy participants with a median follow-up period of 21.9 years completed a questionnaire on socioeconomic and somatic late effects as well as a standardized QoL questionnaire (European Organisation for Research and Treatment of Cancer QLQ-C30). Comparis…

Cancer ResearchState of healthHealth StatusPopulationCohort Studies03 medical and health sciences0302 clinical medicineQuality of lifeSurveys and QuestionnairesHumansMedicineSurvivorsChildeducationSocioeconomic statuseducation.field_of_studyBrain Neoplasmsbusiness.industryConfoundingEditorialsCancermedicine.diseasehumanitiesSocioeconomic FactorsOncology030220 oncology & carcinogenesisCohortQuality of LifeNeurology (clinical)businessPediatric Neuro-Oncology030217 neurology & neurosurgeryCohort studyDemography
researchProduct

Clofarabine Significantly Increases Eradication of Minimal Residual Disease of B-Precursor ALL Compared to High-Dose Cytarabine in Randomized Trial C…

2020

Background Since the FDA approval of clofarabine for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) at childhood, several studies have been launched which put clofarabine under scrutiny in combination with other cytostatic drugs as second or third line therapy. As a novel treatment-strategy we introduced the combination of clofarabine with pegylated asparaginase (PEG-ASP) in a randomized fashion in comparison to the standard consolidation course with high dose cytarabine (Hidac) combined with PEG-ASP into the frontline management of ALL within the CoALL 08-09 protocol. The primary objective of the study was to compare the MRD based assessment of the cytotoxic eff…

medicine.medical_specialtybusiness.industryImmunologyUrologyCell BiologyHematologyBiochemistryMinimal residual diseaselaw.inventionHigh dose cytarabineRandomized controlled triallawmedicineClofarabinebusinessmedicine.drugBlood
researchProduct